Shilpa Medicare gets WHO-Geneva nod for API, Tenofovir Disoproxil Fumarate for HIV, Hepatitis B
Karnataka: Shilpa Medicare Limited has recently announced the receipt of confirmation of WHO - GENEVA approval for API, Tenofovir Disoproxil Fumarate.The medication is used to treat chronic hepatitis B and to prevent and treat HIV / AIDS, under pre-qualification program.Read also: Shilpa Medicare secures DRDO nod for manufacturing anti-COVID drug 2DGShilpa Medicare Limited started...
Login or Register to read the full article
Karnataka: Shilpa Medicare Limited has recently announced the receipt of confirmation of WHO - GENEVA approval for API, Tenofovir Disoproxil Fumarate.
The medication is used to treat chronic hepatitis B and to prevent and treat HIV / AIDS, under pre-qualification program.
Read also: Shilpa Medicare secures DRDO nod for manufacturing anti-COVID drug 2DG
Shilpa Medicare Limited started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989.
Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd